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Abstract
Increasing knowledge on the cell cycle deregulations in cancers has promoted the introduction of
phytochemicals, which can either modulate signaling pathways leading to cell cycle regulation or
directly alter cell cycle regulatory molecules, in cancer therapy. Most human malignancies are
driven by chromosomal translocations or other genetic alterations that directly affect the function
of critical cell cycle proteins such as cyclins as well as tumor suppressors, e.g., p53. In this respect,
cell cycle regulation and its modulation by curcumin are gaining widespread attention in recent
years. Extensive research has addressed the chemotherapeutic potential of curcumin
(diferuloylmethane), a relatively non-toxic plant derived polyphenol. The mechanisms implicated
are diverse and appear to involve a combination of cell signaling pathways at multiple levels. In the
present review we discuss how alterations in the cell cycle control contribute to the malignant
transformation and provide an overview of how curcumin targets cell cycle regulatory molecules
to assert anti-proliferative and/or apoptotic effects in cancer cells. The purpose of the current
article is to present an appraisal of the current level of knowledge regarding the potential of
curcumin as an agent for the chemoprevention of cancer via an understanding of its mechanism of
action at the level of cell cycle regulation. Taken together, this review seeks to summarize the
unique properties of curcumin that may be exploited for successful clinical cancer prevention.
Introduction
Cancers arise by an evolutionary process as somatic cells
mutate and escape the restraints that normally rein in
their untoward expansion. Consequently, multiple mech-
anisms have arisen to forestall uncontrolled cell division.
Some of these are devices within the cell, such as those
that limit cell-cycle progression, whereas others are social
signals that prompt a cell to remain within its supportive
microenvironment. In combination, these tumor-sup-
pressing mechanisms are remarkably effective and can dis-
criminate between neoplastic (abnormally growing) and
normal cellular states and efficiently quell the former
without suppressing the latter.
It is interesting to note that many, perhaps all, networks
that drive cell proliferation harbor intrinsic growth-sup-
pressive properties. Such innate inhibitory functions
obscure any immediate selective advantage that muta-
tions in such pathways might otherwise confer. Because
no single pathway confers a net growth advantage, any
proto-cancer cell acquiring any single oncogenic mutation
is effectively trapped in an evolutionary cul-de-sac. By
contrast in normal cells, coordinated extra-cellular cues
activate multiple pathways in concert. In this way the
inherent growth-suppressive activity of each pathway is
gated by another, thereby unlocking the cell's proliferative
potential. However, de-regulation of one or more of these
activities may ultimately lead to cancer.
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It is acknowledged that cancer results from the interaction
of genetic susceptibility and environmental exposures. It
is, therefore, not very unexpected that there are striking
variations in the risk of different cancers by geographic
area. These geographical variations indicate that there is
clearly a strong environmental component to the risk dif-
ferences. These patterns reflect in one hand prevalence of
specific risk factors and on the other raise the possibility
of presence of anti-cancer agents in the diet differentially
depending on the food habit. Supporting both, migrant
populations from high-risk parts of the world show a
marked diminution in risk when they move to a lower risk
area [1]. There is growing evidence that populations with
greater reliance on fruits and vegetables in the diet experi-
ence a reduced risk for the major cancers [2]. The major
classes of phytochemicals with disease-preventing func-
tions are antioxidants, detoxifying agents and immunity-
potentiating agents. Such dietary phytochemicals include
curcumin (diferuloylmethane), a major naturally-occur-
ring phenolic compound obtained from the rhizome of
the plant Curcuma longa, which is used as a spice or yellow
coloring agent for foods or drugs [3,4]. This phytochemi-
cal has long been known to have broad antioxidant prop-
erties [5]. Because curcumin can suppress cancer cell
proliferation, induce apoptosis, inhibit angiogenesis, sup-
press the expression of anti-apoptotic proteins while pro-
tecting immune system of the tumor bearer – it may have
untapped therapeutic value [3,6,7].
Recent studies using gene-array approach indicate that in
any given type of cancer 300–500 normal genes have been
altered/modified somehow to result in the cancerous phe-
notype. Although cancers are characterized by the deregu-
lation of cell signaling pathways at multiple steps, most
current anticancer therapies involve the modulation of a
single target. The ineffectiveness, lack of safety, and high
cost of mono-targeted therapies have led to a lack of faith
in these approaches. As a result, many pharmaceutical
companies are increasingly interested in developing
multi-targeted therapies. Many plant-based products,
however, accomplish multi-targeting naturally and, in
addition, are inexpensive and safe compared to synthetic
agents. However, because pharmaceutical companies are
not usually able to secure intellectual property rights to
plant-based products, the development of plant-based
anticancer therapies has not been prioritized. Nonethe-
less, curcumin, a plant-based product, has shown signifi-
cant promise against cancer and other inflammatory
diseases.
In the present review we discuss how alterations in the cell
cycle control contribute to the malignant transformation
of normal cells and provide an overview of how curcumin
targets cell cycle regulators to assert its anti-neoplastic
effects. The purpose of the current article is to present an
appraisal of the current level of knowledge regarding the
potential of curcumin as an agent for the chemopreven-
tion of cancer via an understanding of its mechanism of
action at the level of cell cycle regulation.
Cancer: cycle out of hand
Cell proliferation and cell death are such diametrically
opposed cellular fates that how the two are linked and
interdependent processes was a great surprise [8,9]. There
is little mechanistic overlap between the machineries driv-
ing proliferation and apoptosis. Rather, the two processes
are coupled at various levels through the individual
molecular players responsible for orchestrating cell
expansion. Importantly, the same players are often targets
for oncogenic mutations, and in many instances, muta-
tions that drive proliferation cooperate with those that
uncouple proliferation from apoptosis during transforma-
tion and tumorigenesis [10,11]. But, although the phe-
nomenon of oncogene-induced apoptosis is now
generally accepted as an innate tumor-suppressive mech-
anism, we have only recently begun to glimpse the diver-
sity and complexity of mechanisms by which oncogenic
lesions engage the cell suicide machinery.
In normal cells there is a finely controlled balance
between growth promoting and growth restraining signals
such that proliferation occurs only when required. The
balance tilts when increased cell numbers are required,
e.g., during wound healing and during normal tissue turn
over [12]. Proliferation and differentiation of cells during
these processes occur in ordered manner and cease when
no longer required. In tumor cells this process disrupts,
continued cell proliferation occurs and loss of differentia-
tion may be found. In addition, the normal process of
programmed cell death that exists in normal cells may no
longer operate [12]. In other words, a normal cell
becomes malignant when the cellular proliferation is no
longer under normal growth control. There are of course
other characteristics that cancer cell may possess, such as
angiogenesis, metastasis and suppression of apoptosis.
But at the end the uncontrolled proliferation of the cell is
at the heart of the disease. Therefore to understand cancer
we need to transpire our knowledge on cell proliferation
and its control.
The process of replicating DNA and dividing a cell can be
described as a series of coordinated events that compose a
"cell division cycle". The mammalian cell cycle has been
divided into a series of sequential phases. The G1, S, G2,
and M phases are sequentially transitioned in response to
growth factor or mitogenic stimulation (Figure 1). The
DNA synthetic (S phase) and mitotic (M phase) phases
are preceded by gap phases (G1, G2). Cell proliferation is
tightly regulated by multiple interactions between mole-
cules in normal cells. One molecular system sensesCell Division 2008, 3:14 http://www.celldiv.com/content/3/1/14
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growth-promoting conditions and sends a signal to a sec-
ond set of molecules that actually regulates cell division.
In addition, cells are equipped with signaling pathway
that can sense unfavorable conditions for proliferation.
This pathway antagonizes the proliferative signaling path-
way and can directly block cell division [13-15]. Loss of
integrity of these signaling pathways due to mutations can
result in a hyper-proliferative state of cells, manifested as
cancer [9,10]. Therefore, cancer is a disease of deregulated
cell proliferation. It is becoming clear that many external
signals including both those that stimulate growth, such
as growth factors, and those that inhibit growth, such as
DNA damaging agents, control cell proliferation through
regulating the cell cycle. Thus, elucidating the machinery
of cell cycle progression and its regulation by these signals
is essential for understanding and controlling cell prolif-
eration. Recent advances in our understanding of the cell
cycle machinery in the last years have demonstrated that
disruption of normal cell cycle control is frequently
observed in human cancer [10,15].
Cyclin-dependent pathway: the fuel of cell cycle
At least two types of cell cycle control mechanisms are rec-
ognized: a cascade of protein phosphorylations that relay
a cell from one stage to the next and a set of checkpoints
that monitor completion of critical events and delay pro-
gression to the next stage if necessary. The first type of con-
trol involves a highly regulated kinase family [13-15].
Kinase activation generally requires association with a sec-
ond subunit that is transiently expressed at the appropri-
ate period of the cell cycle; the periodic "cyclin" subunit
associates with its partner "cyclin-dependent kinase"
The cell division cycle and its control Figure 1
The cell division cycle and its control. The cell cycle is divided into four distinct phases (G1, S, G2, and M). The progres-
sion of a cell through the cell cycle is promoted by CDKs, which are positively and negatively regulated by cyclins and CKis, 
respectively. As shown, cyclin D isoforms interact with CDK4 and CDK6 to drive the progression of a cell through G1. Cyclin 
D/CDK4,6 complexes phosphorylate pRb, which releases E2F to transcribe genes necessary for cell cycle progression. The 
association of cyclin E with CDK2 is active at the G1-S transition and directs entry into S-phase. The INK4s bind and inhibit 
cyclin D-associated kinases (CDK4 and CDK6). The kinase inhibitor protein group of CKi, p21Cip1/Waf-1, p27Kip1, and 
p57Kip2, negatively regulate cyclin D/CDK4,6 and cyclin E/CDK2 complexes. S-phase progression is directed by the cyclinA/
CDK2 complex, and the complex of cyclin A with Cdk1 is important in G2. CDK1/cyclin B is necessary for the entry into mito-
sis. Curcumin modulates CKis, CDK-cyclin and Rb-E2F complexes to render G1-arrest and alters CDK/cyclin B complex for-
mation to block G2/M transition.Cell Division 2008, 3:14 http://www.celldiv.com/content/3/1/14
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(CDK) to create an active complex with unique substrate
specificity. Regulatory phosphorylation and dephosphor-
ylation fine-tune the activity of CDK-cyclin complexes,
ensuring well-delineated transitions between cell cycle
stages. The orderly progression through G1 phase of the
cell cycle is regulated by the sequential assembly and acti-
vation of three sets of cyclin-CDK complexes (Figure 2),
the D cyclins (D1, D2 and D3) and CDK4 or CDK6, cyclin
E and CDK2, cyclin A and CDK2 [14,15]. Genetic aberra-
tions in the regulatory circuits that govern transit through
the G1 phase of the cell cycle occur frequently in human
cancer, and deregulated over-expression of cyclin D1 is
one of the most commonly observed alterations that may
serve as a drive oncogene through its cell-cycle regulating
function [16]. In normal cells cyclin D1 expression is
tightly regulated by mitogenic signals involving Ras path-
way [17]. Increased cyclin D1 abundance occurs relatively
early during tumorigenesis [18]. In most cancer types cyc-
lin D1 over-expression results from induction by onco-
genic signals, rather than a clonal somatic mutation or
rearrangement in the cyclin D1 gene [19]. Tissue culture-
based experiments evidenced cyclin D1 functions as a col-
laborative oncogene that enhances oncogenic transforma-
tion of other oncogenes (i.e., Ras, Src, E1A) [20,21].
Targeted expression of cyclin D1 or cyclin E induce mam-
mary tumors [22,23]. The cyclin D- and E-dependent
kinases contribute sequentially to the phosphorylation of
the retinoblastoma gene susceptibility product (pRB),
canceling its ability to repress E2F transcription factors
and activating genes required for S phase entry [13,14].
Although the RB-1 gene was first identified through its
role in a rare pediatric cancer, subsequent tumor studies
have shown that this gene is sporadically mutated in a
wide range of cancers [24]. In addition to direct mutation
of the RB-1 gene, its encoded protein (pRB) is functionally
inactivated in many tumor cells either by viral proteins
that bind to pRB, or through changes in a regulatory path-
way that controls the activity of pRB. Current mutation
data indicates that nearly all tumor cells contain muta-
tions or gene silencing events that effectively lead to inac-
tivation of pRB. This establishes that pRB is necessary for
restricting entry into the cell cycle and preventing cancer.
This cyclin-CDK-mediated pathway leading to G1-S tran-
sition is known as "cyclin-dependent pathway". Regula-
tion of G1-CDK activity is affected by their association
with inhibitory proteins, called CDK inhibitors (CKi)
[25]. So far, two families of CKi have been defined based
on their structure and CDK targets: the Ink4 family and
the Cip/Kip family [26]. The inhibitors of Ink4 family
(p15Ink4b, p16Ink4a, p18Ink4c and p19Ink4d) bind to mono-
meric Cdk4 and Cdk6 but not to Cdk2, thereby preclud-
ing the association of these Cdks to cyclins D [27].
Conversely, the members of Cip/Kip family, that include
p21Cip1/Waf-1, p27Kip1 and p57Kip2, all contain characteristic
motifs at their N-terminal moieties that able them to bind
both CDK and cyclins (Figure 1) [26,28]. It can thus be
envisaged from the above discussion that any deregula-
tion of this cyclin-dependent pathway can jeopardize the
normal cell cycle progression and also that alteration of
such deregulation can be one of the targets of cancer ther-
apy. Therefore, the regulation of G1-S and G2-M transi-
tion could be an effective target to control the growth and
proliferation of cancer cells, and facilitate their apoptotic
death.
The ARF-p53 circuit in tumour development and therapy Figure 2
The ARF-p53 circuit in tumour development and 
therapy. Activation of Myc and Ras can force proliferation 
or trigger apoptosis. These oncogenic signals engage the 
tumor-suppressor network at many points, including through 
the ARF-p53 circuit shown here. Which components con-
tribute most to tumor suppression depends on context. For 
example, Myc activates p53 to promote apoptosis while 
interfering with its ability to induce growth arrest by p21. 
Conversely, Ras activates p53 to promote growth arrest 
while suppressing apoptosis. This simplified view helps 
explain why, despite the potential of p53 to control several 
processes; apoptosis is primarily responsible for p53-medi-
ated tumor suppression. DNA damage and oncogene signal-
ing engage the tumor-suppressor network at different points 
and, as such, DNA-damage signaling relies more on p53 than 
on ARF to elicit an anti-proliferative response. Such a model 
explains why loss of ARF or p53 confers similar advantages 
during Myc-induced tumorigenesis but not following treat-
ment with DNA-damaging drugs such as curcumin. Here, 
drug resistance is an unselected trait conferred by p53 muta-
tions that provides a unique advantage as the tumor encoun-
ters a new environment (e.g., chemotherapy).Cell Division 2008, 3:14 http://www.celldiv.com/content/3/1/14
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p53: the master regulator
Besides "cyclin-dependent pathway", as a tumor suppres-
sor, p53 has a central role in cell cycle regulation. How-
ever, this second type of cell cycle regulation, checkpoint
control, is more supervisory. It is not an essential part of
the cell cycle progression machinery. Cell cycle check-
points sense flaws in critical events such as DNA replica-
tion and chromosome segregation [29]. When
checkpoints are activated, for example, by under-repli-
cated or damaged DNA, signals are relayed to the cell
cycle-progression machinery. These signals cause a delay
in cell cycle progression, until the danger of mutation has
been averted. Because checkpoint function is not required
in every cell cycle, the extent of checkpoint function is not
as obvious as that of components integral to the process,
such as CDKs. Researches conducted in the last two dec-
ades have firmly established the importance of p53 in
mediating the cell cycle arrest that occurs following DNA
damage, thus acting as a molecular "guardian of genome"
(Figure 2) [8,30,31]. However, during the same time, the
role of p53 in mediating apoptosis has become increas-
ingly less clear, even as the number of putative pro-apop-
totic proteins trans-activated by p53 has increased [8].
Numerous studies have analyzed the pattern of genes
induced after p53 activation using global technologies
such as SAGE, DNA array, Suppression Subtractive
Hybridization or by cloning functional p53-binding sites.
These studies emphasize the heterogeneity of the p53
response that is highly variable depending on the cell
type, the nature and amount of DNA damage, the genetic
background of the cells and the amount of p53 protein.
Similarly unclear is how p53 makes a choice between cell-
cycle arrest and apoptosis raising the possibility that p53
alone is not responsible for this crucial decision. An
important function of p53 is to act as a transcription fac-
tor by binding to a p53-specific DNA consensus sequence
in responsive genes, which would be expected to increase
the synthesis of p21Cip1 or Bax [8,30,31].
Up-regulation of p21Cip1/p21Waf-1 results in the inhibition
of cell cycle progression from G1 to S phase of cell cycle
[32]. Interestingly, at Cip1, p53 pathway meets cyclin-
dependent pathway. p21Cip1 binds to cyclin-CDK com-
plex, inhibits kinase activity and blocks cell cycle progres-
sion [32]. However, the underlying mechanism is still not
yet fully revealed. Since the stabilization of another mem-
ber of CKi family, p27Kip1, by phosphorylation prevents
inhibition of Cdk/cyclin complexes in the ternary com-
plex and blocks cell cycle progression [26,33,34], similar
mechanism might be operative in case of p21Cip1. The
available evidence suggests that Cip1-PCNA complexes
block the role of PCNA as a DNA polymerase processivity
factor in DNA replication, but not its role in DNA repair.
Thus, Cip1 can act on cyclin-CDK complexes and PCNA
to stop DNA replication. The removal of both Cip1 alleles
from a cancerous cell line in culture that contained a wild-
type p53 allele completely eliminated the DNA damage-
induced G1 arrest in these cells, indicating that Cip1 is
sufficient to enforce a G1 arrest in this experimental situ-
ation [35].
Another group of important regulators of apoptosis is the
Bcl-2 family. These oncoproteins are classified into two
groups: anti-apoptotic that inhibits apoptosis and pro-
apoptotic that induces or accelerates it. The members
form heterodimers to inactivate each other. The up-regu-
lation of Bax expression and down-regulation of Bcl-2
have been demonstrated during apoptosis [32-36]. Inter-
estingly, Bcl-2 over-expression renders cells resistant to
apoptosis when it homodimerizes, whereas, up-regula-
tion of Bax alters Bcl-2/Bax ratio in cellular microenviron-
ment and cause release of cytochrome c from
mitochondria into cytosol [37]. Cytochrome c then binds
to Apaf-1 and activates caspase cascade, which is respon-
sible for the later process of apoptosis [38]. Therefore, in
one hand, deregulation of these cell cycle regulators leads
to cancer and on the other any agent that can regulate
these processes in cancer cells may have a role in tumor
regression.
Cell cycle and apoptosis: two sides of the same coin
The fundamental processes of progression through the
cell cycle and of programmed cell death involve the com-
plex interaction of several families of proteins in a system-
atic and coordinated manner. They are separate, distinct
processes that are intimately related and together play an
important role in the sensitivity of malignant cells to
chemotherapy. The cell cycle is the mechanism by which
cells divide. Apoptosis is an active, energy-dependent
process in which the cell participates in its own destruc-
tion. The cell cycle and apoptosis are intimately related, as
evidenced by the central role of p53, both in cell cycle
arrest and in the induction of apoptosis. Another example
of this intimate relation was demonstrated in human
colon cancer cell lines that differ only in their p21 check-
point status. Cells with wild-type p21, when irradiated
with γ-radiation, underwent a cell cycle growth arrest fol-
lowed by clonogenic survival, where as cells lacking p21,
when irradiated with γ-radiation, did not undergo a cell
cycle growth arrest and furthermore proceeded to apopto-
sis [39]. Cells that undergo a growth arrest may be pro-
tected from apoptosis and may therefore be ultimately
resistant to the cytotoxic agent.
Curcumin – the curry for cure: our hypothesis
Cell cycle progression is an important biological event
having controlled regulation in normal cells, which
almost universally becomes aberrant or deregulated in
transformed and neoplastic cells. In this regard, targeting
deregulated cell cycle progression and its modulation byCell Division 2008, 3:14 http://www.celldiv.com/content/3/1/14
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various natural and synthetic agents are gaining wide-
spread attention in recent years to control the unchecked
growth and proliferation in cancer cells. In fact, a vast
number of experimental studies convincingly show that
many phytochemicals halt uncontrolled cell cycle pro-
gression in cancer cells. Among these phytochemicals,
curcumin has been identified as one of the major natural
anticancer agents exerting anti-neoplastic activity in vari-
ous types of cancer cells. Here we hypothesize that curcu-
min asserts its anti-tumor activity in cancer cells by
altering the de-regulated cell cycle via (a) cyclin-depend-
ent, (b) p53-dependent and (c) p53-independent path-
ways.
At the crossroads of alternative and main stream medicine
Turmeric has been used for thousands of years in
Ayurvedic and traditional Chinese medicine. In modern
times, curcumin, the yellow pigment of the spice turmeric,
continues to be used as an alternative medicinal agent in
many parts of South East Asia for the treatment of com-
mon ailments such as stomachic upset, flatulence, jaun-
dice, arthritis, sprains, wounds and skin infections among
many others. Curcumin and turmeric products have been
characterized as safe by health authorities such as the
Food and Drug Administration (FDA) in United States of
America, Food and Agriculture Organization/World
Health Organization (FAO/WHO). Curcumin has entered
scientific clinical trials at the phase I and II clinical trial
level only in the last 10–15 years. A phase III study of gem-
citabine, curcumin and celecoxib is due to open to recruit-
ment at the Tel-Aviv Sourasky Medical Center for patients
with metastatic colorectal cancer [40].
Why curcumin?
Curcumin is a component of turmeric; the yellow spice
derived from the roots (rhizomes) of the plant Curcuma
longa. Curcuma longa is a short-stemmed perennial, which
grows to about 100 cm in height. It has curved leaves and
oblong, ovate or cylindrical rhizomes (Figure 3). Curcuma
longa grows naturally throughout the Indian subcontinent
and in tropical countries, particularly South East Asia. A
traditional remedy in "Ayurvedic medicine" and ancient
Indian healing system that dates back over 5,000 years,
turmeric has been used through the ages as an "herbal
aspirin" and "herbal cortisone" to relieve discomfort and
inflammation associated with an extraordinary spectrum
of infectious and autoimmune diseases [4].
Curcumin, chemically it is known as diferuloylmethane
(C21H20O6), has been the subject of hundreds of pub-
lished papers over the past three decades, studying its anti-
oxidant, anti-toxic, anti-inflammatory, cancer
chemopreventive and potentially chemotherapeutic prop-
erties [3,4,41-44]. The pharmacology and putative anti-
cancer properties of curcumin have been the subject of
several review articles published since 1991, which pre-
Curcuma longa Plant and chemical structure of curcumin, the active ingradient of rhizome termeric Figure 3
Curcuma longa Plant and chemical structure of curcumin, the active ingradient of rhizome termeric. The tau-
tomerism of curcumin is demonstrated under different physiological conditions. Under acidic and neutral conditions, the bis-
keto form (bottom) is more predominant than the enolate form.Cell Division 2008, 3:14 http://www.celldiv.com/content/3/1/14
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date a number of clinical studies of curcumin which have
been completed and published within the last few years
[45]. But these properties do not prove the superiority of
this phytochemical over other chemotherapeutic agents
that also induced apoptosis successfully in cancer cells.
Majority of chemotherapeutic agents, including those iso-
lated from plants (such as taxol or vincristin etc.) not only
induce cancer cell apoptosis but also severely damage the
normal cells of the host, the effects being particularly
severe in case of the immune system [46]. On the con-
trary, curcumin is a part of our daily food habit and its use
in large quantities from ancient time has already proved
that it is a safe product [4]. In fact, since curcumin prefer-
ably induces apoptosis in highly proliferating cells, death
is much more pronounced in tumor cells than normal
ones [47]. Report from our laboratory has shown that
anticancer dose of curcumin arrests non-malignant cells
in G0 phase reversibly but does not induce apoptosis in
them [6]. Further studies revealed that this phytochemical
protects T cells of the cancer bearer from cancer as well as
chemotherapeutic agent-induced apoptosis [7,47]. The
basis of this differential regulation may be attributed to its
differential effects on normal and neoplastic cell cycles
since deregulation of some components of cell cycle regu-
latory machinery can drive uncontrolled proliferation and
hence neoplastic transformations.
The broad biological activity of this phytochemical,
including antioxidant and metabolic effect, influences
upon key signal transduction pathways of cell cycle and
effectiveness in animal model systems have fostered
development of translational, and clinical research pro-
grams. In pilot clinical studies in India, Taiwan, USA and
UK, curcumin has been associated with regression of pre-
malignant lesions of the bladder, soft palate, GI tract, cer-
vix, and skin, and with treatment responses in established
malignancy [48-52]. Doses up to 8–10 g could be admin-
istered daily to patients with pre-malignant lesions for 3
months without overt toxicity [48-50]. It cannot be
assumed that diet-derived agents will be innocuous when
administered as pharmaceutical formulations at doses
likely to exceed those consumed in the dietary matrix.
Anecdotal reports suggest that dietary consumption of
curcumin up to 150 mg/day is not associated with any
adverse effects in humans [44]. The epidemiological data
interestingly suggest that it may be reason for the lower
rate of colorectal cancer in these countries than in "devel-
oped" countries [1,2]. The preclinical data in human sub-
jects suggest that a daily dose of 3.6 g curcumin achieves
measurable levels in colorectal tissue. Efficient first-pass
and some degree of intestinal metabolism of curcumin,
particularly glucuronidation and sulphation, may explain
its lesser systemic availability when administered via oral
route [53]. So, gastrointestinal tract could represent a pref-
erential chemoprevention target because of its greater
exposure to unmetabolized bioactive curcumin from diet
than other tissues. All these information not only suggest
that curcumin has enormous potential in the prevention
and therapy of cancer but also well justify the utility of
using curcumin as an anti-tumor agent.
To arrest or to kill – two weapons of curcumin
It is now apparent that many of the phytochemicals pref-
erentially inhibit the growth of tumor cells by inducing
cell cycle arrest or apoptosis (Figure 2). The anti-tumor
effect of curcumin has also been attributed in part to the
suppression of cell proliferation, reduction of tumor load
and induction of apoptosis in various cancer models both
in vitro and in vivo [6,44,48,49,54-57]. Curcumin inhibits
multiple levels within transcriptional network to restrict
cell proliferation. It induces p53-dependent apoptosis in
various cancers of colon, breast, bladder, neuron, lung,
ovary etc., although both p53-dependent and -independ-
ent G2/M phase arrest by curcumin has been observed in
colorectal cancer cells [6,48,49,57-61]. Curcumin pro-
motes caspase-3-mediated cleavage of β-catenin,
decreases β-catenin/Tcf-Lef transactivation capacity for c-
Myc and cyclin D1 [62]. It also activates caspase-7 and cas-
pase-9 and induces polyadenosine-5'-diphosphate-ribose
polymerase cleavage through the down-regulation of
NFκB in multiple myeloma cells [63]. Furthermore, curcu-
min inhibits EGFR activation [64], Src activity [65] and
inhibits activity of some nuclear receptors [66]. Curcumin
inhibitory effects upon Cox-2 and cyclin D1, mediated
through NF-κB, also restrict tumor cell growth [62,67].
Induction of G2/M arrest and inhibition of Cox-2 activity
by curcumin in human bladder cancer cells has also been
reported [58]. It induces colon cancer cell apoptosis by
JNK-dependent sustained phosphorylation of c-Jun [68]
and enhances TNF-α-induced prostate cancer cell apopto-
sis [70]. In fact, curcumin induces apoptosis in both
androgen-dependent and androgen-independent prostate
cancer cells [70]. On the other hand, in breast carcinoma
cells, it inhibits telomerase activity through human telom-
erase reverse-transcritpase [71]. In Bcr-Abl-expressing
cells, G2/M cell cycle arrest, together with increased
mitotic index and cellular as well as nuclear morphology
resembling those described for mitotic catastrophe, was
observed and preceded caspase-3 activation and DNA
fragmentation leading to apoptosis [72]. Curcumin
arrested cell growth at the G2/M phase and induced apop-
tosis in human melanoma cells by inhibiting NFκB activa-
tion and thus depletion of endogenous nitric oxide [73].
However, in mantle cell lymphoma curcumin has been
found to induce G1/S arrest and apoptosis [74]. In T cell
leukemia curcumin induced growth-arrest and apoptosis
in association with the inhibition of constitutively active
Jak-Stat pathway and NFκB [75,76]. Holy [77] reported
disruption of mitotic spindle structure and induction ofCell Division 2008, 3:14 http://www.celldiv.com/content/3/1/14
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micronucleation in human breast cancer cells by this yel-
low pigment. Besides arresting growth or inducing apop-
tosis, curcumin also enhances differentiation by targeting
PI3K-Akt pathway, Src-mediated signaling and PPAR
[64,65,78]. This action of curcumin promotes cells exit
from cycle. All these reports indicate that curcumin might
be asserting its anti-cancer effect by modulating cancer cell
cycle regulatory machineries.
Curcumin: the manipulator of cyclin pathway
It is clear that curcumin spares normal cell from apoptotic
induction making it a relatively safe anti-cancer agent. The
question thus arises that what confers this selectivity. In
an attempt to understand the basic mechanisms of car-
cinogenesis, it was found that, in slowly-proliferating
non-malignant cells, Ras activity is stimulated to high
level at G1 phase upon mitogenic challenge and leads to
cyclin D1 elevation during mid to late G1 phase [13-16].
Interestingly, we found that this pattern, upon which
most models of cell cycle regulation are based, does not
apply to actively proliferating cancer cells. In fact, in these
rapidly cycling cells, oncogenic Ras is active throughout
the cell cycle during exponential growth and induces high
levels of cyclin D1 expression in G2 phase that continues
through mitosis to G1 phase bypassing G0 phase, a phase
that regulates uncontrolled proliferation [79-81]. These
results not only demonstrated that the critical signaling
events upon which cell cycle progression depends take
place during G1 phase in normal cells, but during G2
phase in actively growing cancer cells but also that G2
phase of cell cycle plays a critical role in controlling hyper-
proliferative status of cancer cell and is thus susceptible to
successful anti-cancer drug therapy.
With elegant time-lapse video-micrography and quantita-
tive imaging approach our works with breast malignant
cells and adjacent non-malignant cells indicate that curcu-
min did not alter the cell cycle progression of carcinoma
cells, although it induced apoptosis in the same at G2
phase of cell cycle (Figure 4) while reversibly blocking
non-malignant cell cycle progression without apoptosis
[6]. An interesting finding in this study was that curcumin
appeared to be sparing the normal epithelial cells by
arresting them at the G0 phase of the cell cycle via down-
regulation of cyclin D1 and its related protein kinases or
up-regulation of the inhibitory protein. The experiments
with cyclin D1-deregulated cells showed that curcumin
did not alter cyclin D1 expression level in cancer cells, but
in normal cells, where cyclin D1 expression is tightly reg-
ulated by mitogenic signaling, its expression is inhibited
by curcumin. This inability of curcumin to inhibit cyclin
D1 expression in cyclin D1-deregulated cells may serve as
the basis for differential regulation of cancerous and nor-
mal cells. In addition, curcumin was found to inhibit the
association of cyclin D1 with CDK4/CDK6 or phosphor-
ylation of pRb in some cancer cells where the expression
of cyclin D1 is not deregulated and thus arrest them at G0/
G1 phase (Figure 1) [82,83]. This yellow pigment has
been shown to inhibit neoplastic cell proliferation by
decreasing Cdk1 kinase activity and arresting cells at G2/
M check point [81]. Ectopically over-expression of cyclin
D1 renders susceptibility of these cells towards curcumin
toxicity [6]. These results may well explain why in cancer
cells, despite up-regulation of p53 and increase in Cip1
level, there was no cell cycle arrest. In fact, the level of cyc-
lin D1 is very high in these cells and remained unchanged
upon curcumin treatment. Thus, the amount of Cip1, as
up regulated by curcumin, was still not sufficient to over-
power cyclin D1 and to stop cell cycle progression. On the
other hand, in non-malignant cells, the level of Cip1
increased dramatically with parallel down-regulation of
cyclin D1, thereby making the ratio of Cip1 to cyclin D1 >
1 and this might be one of the causes of cell cycle arrest
without apoptosis [6]. The above discussion not only
relates curcumin activity with cell cycle regulation but also
explains the mechanism underlying the differential effect
of this phytochemical in normal and malignant cells.
Curcumin regulating "guardian of genome"
The tumor suppressor gene p53, acknowledged as the
"guardian of genome", is situated at the crossroads of a net-
work of signaling pathways that are essential for cell
growth regulation and apoptosis [30-35]. In normal
unstressed cells, these upstream pathways predominantly
include the binding by proteins such as Mdm2 that pro-
mote p53 degradation via the ubiquitin-26S proteasome
pathway [32]. COP9 signalosome (CNS)-specific phos-
phorylation targets p53 to ubiquitin-26S proteasome-
dependent degradation. Curcumin has been found to
inhibit CSN and block Mdm2- and E6-dependent p53
degradation [84]. Furthermore, in basal cell carcinoma,
curcumin promotes de novo synthesis of p53 protein or
some other proteins for stabilization of p53, and hence
enhances its nuclear translocation to transactivate Cip1
and Gadd45 indicating that p53-associated signaling
pathway is critically involved in curcumin-mediated
apoptotic cell death [56]. With time-lapse video-microg-
raphy and quantitative imaging approach we have dem-
onstrated that in deregulated cells, curcumin induces p53
dramatically at G2 phase of cell cycle and enhances p53
DNA-binding activity resulting in apoptosis at G2 phase
(Figure 4) [6,47]. On the other hand, curcumin increases
p53 expression to a lower extent throughout the cell cycle
in non-malignant cells [6]. In these cells, curcumin revers-
ibly up-regulates Cip1 expressions and inactivates pRB
and thus arrests them in G0 phase of cell cycle. Therefore,
these cells escape from curcumin-induced apoptosis at G2
phase. Works from other laboratories also suggest that
curcumin induces p53 expression in colon, breast, and
other cancer cells [57-61]. Reports from our laboratory asCell Division 2008, 3:14 http://www.celldiv.com/content/3/1/14
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well as from other laboratories suggest that curcumin pre-
dominantly acts in a p53-dependent manner as careful
analysis of the effect of curcumin in various cells express-
ing wild-type or mutated p53 as well as cells transfected
with dominant-negative p53, revealed that the cells
expressing high levels of wild-type p53 were more sensi-
tive to curcumin toxicity. On the other hand, p53-knock-
out as well as p53-mutated cells also showed toxicity,
although the apoptotic-index is lower [6,42,47].
Search for downstream of p53 revealed that in mammary
epithelial carcinoma and colon adenocarcinoma cells cur-
cumin could increase the expression of the pro-apoptotic
protein Bax and decrease the anti-apoptotic protein Bcl-2/
Bcl-xL through the phosphorylation at Ser15 and activa-
tion of p53 [6,85]. Our results also revealed curcumin-
induced G2/M arrest and apoptosis of mammary epithe-
lial carcinoma cells via  p53-mediated Bax activation
[6,47]. On the other hand, c-Abl, a non-receptor tyrosine
kinase, has been reported to play an important role in cur-
cumin-induced cell death through activation of JNK and
induction of p53 [86].
All these reports indicate that curcumin can induce cancer
cell killing predominantly via  p53-mediated pathway,
p53 not only controls apoptotic pathways but also acts as
a key cell cycle regulatory protein as it can trans-activate
cell cycle inhibitors like Cip1 on the event of DNA dam-
age during proliferation and when the damage is irrepara-
ble it induces apoptosis by inducing the expression of pro-
apoptotic proteins like Bax (Figure 2). So far our discus-
sion thus clearly indicates the involvement of the guardian
of genome, p53, in curcumin-induced cancer cell apoptosis
via cell cycle regulation.
Time-lapse determination of approximate cell cycle position of curcumin-induced apoptosis Figure 4
Time-lapse determination of approximate cell cycle position of curcumin-induced apoptosis. Time-lapse video-
micrography was employed to monitor curcumin-induced apoptosis of breast cancer cells. Age of each cell was analyzed from 
a time-lapse analysis before curcumin addition. The occurrence and the time of apoptosis after curcumin addition were deter-
mined from a time-lapse analysis after addition.Cell Division 2008, 3:14 http://www.celldiv.com/content/3/1/14
Page 10 of 14
(page number not for citation purposes)
p53-independent pathways and curcumin
It is evident that curcumin can induce selective cancer cell
killing in a p53-dependent manner, but impaired p53
expression or activity is associated with a variety of neo-
plastic transformations. Increasing reports are indicating
that curcumin can block cell cycle progression or even
apoptosis in a p53-independent manner as well, espe-
cially in the cells that lack functional p53 [83]. Curcumin
induces apoptosis in p53-null lung cancer cells [61]. It
induces melanoma cell apoptosis by activating caspase-8
and caspase-3 via Fas receptor aggregation in a FasL-inde-
pendent manner, blocks NFκB cell survival pathway and
suppresses the apoptotic inhibitor XIAP [87]. Curcumin
inhibits cellular isopeptidases, and cause cell death inde-
pendently of p53 in isogenic pairs of RKO and HCT 116
cells with differential p53 status [88]. It enhances the
chemotherapy-induced cytotoxicity in p53-null prostate
cancer cell line PC-3, via up-regulation of Cip1 and C/
EBPβ expressions and suppression of NFκB activation
[89]. It also induces apoptosis in multiple myloma cells
by inhibiting IKK and NFκB activity [64]. Study indicates
that curcumin down regulates NFκB and AP-1 activity in
androgen-dependent and -independent prostate cancer
cell lines [70]. Curcumin is a potent inhibitor of protein
kinase C (PKC), EGF (epidermal growth factor)-receptor
tyrosine kinase and IκB kinase. Subsequently, curcumin
inhibits the oncogenes including c-jun, c-fos, c-myc, NIK,
MAPKs, ELK, PI3K, Akt, CDKs and iNOS [63,90]. In con-
trast to the mentioned reports, studies by Collet et al.
shows that curcumin induces JNK-dependent apoptosis of
colon cancer cells and it can induce JNK-dependent sus-
tained phosphorylation of c-jun and stimulation of AP-1
transcriptional activity [68]. The oxidized form of cancer
chemopreventive agent curcumin can inactivate PKC by
oxidizing the vicinal thiols present within the catalytic
domain of the enzyme [90]. Recent studies indicated that
proteasome-mediated degradation of cell proteins play a
pivotal role in the regulation of several basic cellular proc-
esses including differentiation, proliferation, cell cycling,
and apoptosis. It has also been demonstrated that curcu-
min-induced apoptosis is mediated through the impair-
ment of ubiquitin-proteasome pathway [90]. All these
reports suggests that curcumin can induce apoptosis or
block cell cycle progression in a variety of cancer cell lines,
predominantly via p53-dependent pathways, but it can
also act in a p53-independent manner (Figure 5).
Other functions of curcumin
Curcumin inhibits angiogenesis directly and via regula-
tion of angiogenic growth factors like vascular endothelial
growth factor, basic fibroblast growth factor and epider-
mal growth factor, as well as the genes like angiopoietin 1
and 2, hypoxia-inducible factor-1, heme oxygenase-1, and
the transcriptional factors like NF-κB [40]. Inhibition of
angiogenic growth factor production and metalloprotein-
ase generation, both integral to the formation of new vas-
culature, has also been influenced by curcumin in non-
malignant and malignant cells growth [91,92]. Similar to
the inhibition of angiogenic factors, curcumin has been
shown to regulate proteins related to cell-cell adhesion,
such as β-catenin, E-cadherin and APC and to inhibit the
production of cytokines relevant to tumor growth, e.g.
tumour necrosis factor-α (TNF-α) and interleukin-1
[93,94]. Additionally, curcumin has been shown to
reduce the expression of membrane surface molecules
such as intracellular adhesion molecule-1, vascular cell
adhesion molecule-1 and E-selectin and matrix metalo-
proteases those play important roles in cellular adhesion
and metastasis [3,95].
Curcumin has also been shown to quench reactive oxygen
species and scavenge superoxide anion radicals and
hydroxyl radicals and strongly inhibits nitric oxide (NO)
production by down-regulating inducible nitric oxide syn-
thase gene expression [96,97]. Curcumin inhibits of phase
I enzymes systems consist of cytochrome P450 isoforms,
the P450 reductase, the cytochrome b5 and the epoxide
hydrolase and protect from the toxic effects of chemicals
and carcinogens [60]. On the other hand curcumin
induces phase II enzymes (glutathione S-transferases and
epoxide hydrolase), which play a protective role by elimi-
nating toxic substances and oxidants and conferring ben-
efit in the prevention of the early stages of carcinogenesis
[98].
Curcumin can act as a potent immunomodulatory agent
that can modulate the activation of T cells, B cells, macro-
phages, neutrophils, natural killer cells, and dendritic
cells. Curcumin can also down-regulate the expression of
various pro-inflammatory cytokines including TNF, IL-1,
IL-2, IL-6, IL-8, IL-12, and chemokines, most likely
through inactivation of the transcription factor NF-κB
[99]. Interestingly, however, curcumin at low doses can
also enhance antibody responses. Curcumin has been
shown to activate host macrophages and natural killer
(NK) cells and modulate of lymphocyte-mediated func-
tions [100]. Studies from our laboratory showed that cur-
cumin neutralized tumor-induced oxidative stress,
restored NF-kB activity, and inhibited TNF-α production,
thereby minimizing tumor-induced T-cell apoptosis [7].
Further work suggests that curcumin helps in T cell sur-
vival both in primary and effecter immune compartments
of tumor-bearing hosts by normalizing perturbed of Jak-
3/Stat-5 activity via restoration of IL2-receptor γc chain
expression [101]. Curcumin was found to prevent tumor-
induced loss of T-effector cells, reverse type-2 cytokine
bias and blocks T-regulatory cell augmentation in tumor-
bearing hosts via down-regulation of TGF-β in cancer cells
(unpublished data). From all these observations it is sug-
gested that curcumin may be used alone or can be com-Cell Division 2008, 3:14 http://www.celldiv.com/content/3/1/14
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bined with classical anti-tumor drugs so as to sustain the
immune capacity of the host, which can be affected by the
disease or the treatment or may be the both.
Curcumin – a multiple edged sword
Above discussions on the broad biological activity of this
phytochemical prove our hypothesis that curcumin
asserts its anti-tumor activity in cancer cells by altering the
deregulated cell cycle via (a) cyclin-dependent, (b) p53-
dependent and (c) p53-independent pathways. Such
influences of curcumin upon key signal transduction
pathways of cell cycle and effectiveness in animal model
systems have qualified it as a multiple edged sword in com-
bating the deadly disease – cancer. Given that disruption
of cell cycle plays a crucial role in cancer progression, its
modulation by curcumin seems to be a logical approach
in controlling carcinogenesis. Most of the plant products
with anticancer activity act as strong antioxidants and
some of them are effective modulators of protein kinases/
phosphatases that are associated with cell cycle regula-
tion. Many of these phytochemicals are either part of the
human diet or consumed as dietary supplement, and do
Oncogenic signaling targets many levels curcumin Figure 5
Oncogenic signaling targets many levels curcumin. Curcumin enhances apoptotic death, inhibits deregulated cellular 
proliferation, dedifferentiation and progression towards the neoplastic phenotype by altering key signaling molecules required 
for cell cycle progression. Such a network organization allows the cell to sense many aspects of the intracellular and extra-cel-
lular milieu, yet ensures that cell death proceeds efficiently once activated. Excessive oncogenic signaling is coupled to apopto-
sis by a complex mechanism that targets key control points in the pathways. Blunt-head lines indicate that these molecules can 
be down-regulated by curcumin, where as arrow-head lines indicate that these molecules are often up-regulated by curcumin.Cell Division 2008, 3:14 http://www.celldiv.com/content/3/1/14
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not show adverse health effects even at large doses. Due to
failure of conventional chemotherapy in advance stages of
cancer and its enormous adverse effects, cancer chemopre-
vention by this phytochemical in a defined molecular tar-
get approach will play an important role in future in
reducing cancer incidence as well as the number of deaths
caused by this disease.
Prospects for the future
Previous seminal work, summarized above has demon-
strated curcumin inhibition of key molecular mechanisms
of tumorigenesis. Effects have been shown of common
signaling intermediates that influence the tumor pheno-
type. Major advances in the understanding of cell cycle
regulation mechanisms provided a better knowledge of
the molecular interactions involved in human cancer.
Moreover, the components of the cell cycle are probably
involved in other non-cancerous diseases and their role
must be defined. Further mechanistic work however, is
required to investigate curcumin effects on switches that
connect common effector pathways that regulate cell
behavior, phenotype alteration and cell death or lineage
commitment. Human intervention studies of curcumin,
whether alone or in combination, are indicated against
intermediate biomarkers and morphological stages of gas-
trointestinal tumorigenesis. Curcumin could thus provide
a useful component of dietary or pharmacological treat-
ment aimed at reduction of the incidence of and mortality
from cancer.
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